Bradykinin and Neurotensin Analogues as Potential Compounds in Colon Cancer Therapy

Int J Mol Sci. 2023 Jun 1;24(11):9644. doi: 10.3390/ijms24119644.

Abstract

Colorectal cancer (CRC) is one of the most lethal malignancies worldwide, so the attempts to find novel therapeutic approaches are necessary. The aim of our study was to analyze how chemical modifications influence physical, chemical, and biological properties of the two peptides, namely, bradykinin (BK) and neurotensin (NT). For this purpose, we used fourteen modified peptides, and their anti-cancers features were analyzed on the HCT116 CRC cell line. Our results confirmed that the spherical mode of a CRC cell line culture better reflects the natural tumour microenvironment. We observed that the size of the colonospheres was markedly reduced following treatment with some BK and NT analogues. The proportion of CD133+ cancer stem cells (CSCs) in colonospheres decreased following incubation with the aforementioned peptides. In our research, we found two groups of these peptides. The first group influenced all the analyzed cellular features, while the second seemed to include the most promising peptides that lowered the count of CD133+ CSCs with parallel substantial reduction in CRC cells viability. These analogues need further analysis to uncover their overall anti-cancer potential.

Keywords: bradykinin; colorectal cancer; neurotensin; peptides.

MeSH terms

  • AC133 Antigen
  • Bradykinin* / analogs & derivatives
  • Cell Survival
  • Colonic Neoplasms* / drug therapy
  • HCT116 Cells
  • Humans
  • Neoplastic Stem Cells / drug effects
  • Neurotensin* / analogs & derivatives
  • Peptides / chemical synthesis
  • Peptides / pharmacology

Substances

  • Bradykinin
  • Neurotensin
  • AC133 Antigen
  • Peptides

Grants and funding

This research received no external funding.